These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 23291951)

  • 1. New generation of dendritic cell vaccines.
    Radford KJ; Caminschi I
    Hum Vaccin Immunother; 2013 Feb; 9(2):259-64. PubMed ID: 23291951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro Generation of Human XCR1(+) Dendritic Cells from CD34(+) Hematopoietic Progenitors.
    Balan S; Dalod M
    Methods Mol Biol; 2016; 1423():19-37. PubMed ID: 27142006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing the immunogenicity of cancer vaccines by harnessing CLEC9A.
    Lahoud MH; Radford KJ
    Hum Vaccin Immunother; 2022 Dec; 18(1):1873056. PubMed ID: 33625943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cells and cancer immunotherapy.
    Radford KJ; Tullett KM; Lahoud MH
    Curr Opin Immunol; 2014 Apr; 27():26-32. PubMed ID: 24513968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BDCA3(+)CLEC9A(+) human dendritic cell function and development.
    van der Aa E; van Montfoort N; Woltman AM
    Semin Cell Dev Biol; 2015 May; 41():39-48. PubMed ID: 24910448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-mediated targeting of antigen to C-type lectin-like receptors Clec9A and Clec12A elicits different vaccination outcomes.
    Macri C; Dumont C; Panozza S; Lahoud MH; Caminschi I; Villadangos JA; Johnston AP; Mintern JD
    Mol Immunol; 2017 Jan; 81():143-150. PubMed ID: 27978488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141
    Masterman KA; Haigh OL; Tullett KM; Leal-Rojas IM; Walpole C; Pearson FE; Cebon J; Schmidt C; O'Brien L; Rosendahl N; Daraj G; Caminschi I; Gschweng EH; Hollis RP; Kohn DB; Lahoud MH; Radford KJ
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32737142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of potent CD8 T cell cytotoxicity by specific targeting of antigen to cross-presenting dendritic cells in vivo via murine or human XCR1.
    Hartung E; Becker M; Bachem A; Reeg N; Jäkel A; Hutloff A; Weber H; Weise C; Giesecke C; Henn V; Gurka S; Anastassiadis K; Mages HW; Kroczek RA
    J Immunol; 2015 Feb; 194(3):1069-79. PubMed ID: 25520399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy.
    Zeng B; Middelberg AP; Gemiarto A; MacDonald K; Baxter AG; Talekar M; Moi D; Tullett KM; Caminschi I; Lahoud MH; Mazzieri R; Dolcetti R; Thomas R
    J Clin Invest; 2018 May; 128(5):1971-1984. PubMed ID: 29485973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CLEC9A delivers antigen to human CD141
    Tullett KM; Leal Rojas IM; Minoda Y; Tan PS; Zhang JG; Smith C; Khanna R; Shortman K; Caminschi I; Lahoud MH; Radford KJ
    JCI Insight; 2016 May; 1(7):e87102. PubMed ID: 27699265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A.
    Idoyaga J; Lubkin A; Fiorese C; Lahoud MH; Caminschi I; Huang Y; Rodriguez A; Clausen BE; Park CG; Trumpfheller C; Steinman RM
    Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2384-9. PubMed ID: 21262813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation.
    van Kooyk Y; Unger WW; Fehres CM; Kalay H; García-Vallejo JJ
    Mol Immunol; 2013 Sep; 55(2):143-5. PubMed ID: 23158834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin.
    Sancho D; Mourão-Sá D; Joffre OP; Schulz O; Rogers NC; Pennington DJ; Carlyle JR; Reis e Sousa C
    J Clin Invest; 2008 Jun; 118(6):2098-110. PubMed ID: 18497879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Dressed for success' C-type lectin receptors for the delivery of glyco-vaccines to dendritic cells.
    Unger WW; van Kooyk Y
    Curr Opin Immunol; 2011 Feb; 23(1):131-7. PubMed ID: 21169001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-Presenting XCR1
    Audsley KM; McDonnell AM; Waithman J
    Cells; 2020 Feb; 9(3):. PubMed ID: 32121071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody.
    Tacken PJ; de Vries IJ; Gijzen K; Joosten B; Wu D; Rother RP; Faas SJ; Punt CJ; Torensma R; Adema GJ; Figdor CG
    Blood; 2005 Aug; 106(4):1278-85. PubMed ID: 15878980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses.
    Hutten TJ; Thordardottir S; Fredrix H; Janssen L; Woestenenk R; Tel J; Joosten B; Cambi A; Heemskerk MH; Franssen GM; Boerman OC; Bakker LB; Jansen JH; Schaap N; Dolstra H; Hobo W
    J Immunol; 2016 Oct; 197(7):2715-25. PubMed ID: 27566820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dendritic cells of mucosa and skin: "recruited for vaccination"].
    Le Borgne M; Dubois B; Kaiserlian D
    Med Sci (Paris); 2007 Oct; 23(10):819-25. PubMed ID: 17937889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting vaccines to dendritic cells.
    Foged C; Sundblad A; Hovgaard L
    Pharm Res; 2002 Mar; 19(3):229-38. PubMed ID: 11934227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clec9A
    Gilfillan CB; Kuhn S; Baey C; Hyde EJ; Yang J; Ruedl C; Ronchese F
    J Immunol; 2018 Apr; 200(8):2978-2986. PubMed ID: 29507107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.